Navigation Links
GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
Date:3/6/2013

ZURICH-SCHLIEREN, Switzerland, March 6, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Greco steps down from the Chairmanship.

Gerd Zettlmeissl has more than 20 years of experience in developing and commercializing vaccines. He spent almost 10 years in executive positions at Intercell AG, first as its Chief Operating Officer from 2001 to 2005 and then as its Chief Executive Officer from 2005 until May  2011. Under his leadership, the company received international approval for the novel Japanese encephalitis vaccine, IXIARO®/JESPECT®, formed major strategic alliances with leading pharmaceutical companies, completed several financings, was elected as 'Technology Pioneer' at the World Economic Forum in 2009 and received the European Biotechnica Award in 2006. Before his tenure at Intercell, he served as the international Head of Industrial and Quality Operations at Chiron Vaccines, and Managing Director of Chiron Behring GmbH & Co. He currently serves on the Boards of several biotechnology companies including Aeras, an organization dedicated to the development of tuberculosis vaccines. He holds a Doctorate from the University of Regensburg.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising compa
'/>"/>

SOURCE GlycoVaxyn AG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bayer CropScience Announces Seed Innovation at Pollinator Summit
2. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
3. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
4. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
5. Quantum Cures Announces Breakthrough Approach for Researchers Seeking Cures for Orphan and Rare Diseases
6. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
7. Research and Markets Announces Addition of the "Risk - Reward of Developing a Herceptin Biosimilar - A Thorough Assessment" Report to its Offering
8. Research & Markets Announces the Release of 'Analog Devices ADXL362 3-axis Micropower MEMS Accelerometer Reverse Costing Analysis'
9. Research & Markets Announces the Release of STMicroelectronics LSM303D 6-Axis Electronic Compass - Reverse Costing Analysis
10. Pamlab Announces Agreement for Sale of Business to Nestle Health Science
11. Elsevier Announces the Launch of a New Journal: Methods in Oceanography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
(Date:12/22/2014)... 2014 Fertility Associates of Memphis has ... USA , a network of more than 20 contributing ... patients have fast access to a national pool of ... . Fertility Associates of Memphis is the only fertility ... option. , Dr. William Kutteh , director of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , , BETHESDA, Md., July ... and NWBS) today announces that it will seek shareholder approval for ... AIM market ("AIM") (the "De-listing"). The Company plans to continue its ... Board Market ("U.S. listing"), and plans to file an S1 registration ...
... , SAN DIEGO, July 23 Anadys Pharmaceuticals, Inc. ... quarter 2009 financial results on Thursday, July 30, 2009, after the U.S. ... hold a conference call and webcast on Thursday, July 30, 2009 at ... results and highlights and to provide an update on its development programs. ...
... , SUNNYVALE, Calif., July 23 ... for the treatment of chronic total occlusions (CTOs), today announced the ... Chris previously held the position of Executive VP, Sales and Marketing ... Devices including the last 2 years at FlowCardia. , ...
Cached Biology Technology:Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S. 2Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S. 3Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 2FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... release is available in French . ... action to better control the sale of chemicals that ... Lunn, Minister of Natural Resources, and the Honourable Stockwell ... regulations for these chemicals, known as explosives precursors, will ...
... American,Association of Airport Executives President Chip ... Traveler (RT) program with the opening of,RT ... Reagan,Washington National Airport., "The expansion of ... in,the nation,s capital will further highlight the ...
... — Robots are fluent in their native language of 1 ... imprecise nature of human language. While scientists are making slow, ... responds to speech, gestures and body language, a more straightforward ... homes sooner. A team of researchers led by Charlie ...
Cached Biology News:New regulations tighten controls on restricted chemicals 2AAAE Applauds Expansion of Registered Traveler Program to Nation's Capital 2AAAE Applauds Expansion of Registered Traveler Program to Nation's Capital 3Robot fetches objects with just a point and a click 2Robot fetches objects with just a point and a click 3Robot fetches objects with just a point and a click 4
...
Request Info...
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Biology Products: